PI3K / Akt Signaling
Akt Antibody
|
イイネ!(4)
|
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #9272S | 100 μL | 46,000 | |
|
Akt抗体製品一覧
9272 の推奨プロトコール
最適な結果を得るために:Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注:各製品に最適化されたプロトコールをリンクしています。
| | |
-
9272:
-
Flow
Immunofluorescence
Immunoprecipitation
Western Blotting
| 用途(希釈倍率) | |
| ウェスタンブロッティング(1:1,000)、免疫沈降(1:50)、免疫蛍光細胞染色(IF-IC)(1:200)、フローサイトメトリー(1:50) |
| 種交差性 | |
| ヒト、マウス、ラット、サル、ブタ、ニワトリ、ハムスター、ウシ、モルモット、キイロショウジョウバエ、(イヌ) |
| 特異性・感度 | |
| 内在性レベルのAkt1、Akt2 およびAkt3 タンパク質を検出します。他の関連するキナーゼとは交差しません。 |
| 使用抗原 | |
| マウスのAkt タンパク質のC末端領域(合成ペプチド) |
| ※括弧付きの動物種は配列が100%相同であるため反応すると推定されます。 |
Western Blotting

Western blot analysis of extracts from CHO cells, transfected with non-targeted (-) or SignalSilence® Akt siRNA I (+) siRNA, using Akt Antibody #9272 and p42 MAP Kinase (Erk2) Antibody #9108. The Akt antibody confirms silencing of protein expression while the p42 MAP Kinase (Erk2) antibody was used to control for loading and specificity of Akt siRNA (A). Phospho-GSK-3β (Ser9) Antibody #9336 was used to confirm downstream pathway inhibition (B).
Western Blotting

Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 (-) or SignalSilence® Akt siRNA I (+), using Akt Antibody #9272 and p42 MAP Kinase (Erk2) Antibody #9108. Akt antibody confirms silencing of Akt expression, while the p42 MAP kinase (Erk2) antibody is used to control for loading and specificity of Akt siRNA.
Western Blotting

Western blot analysis of extracts from NIH/3T3 cells, untreated or PDGF-treated (50 ng/ml) for the indicated times, using Phospho-Akt (Ser473) Antibody #9271 (upper) or Akt Antibody (lower).
Flow Cytometry

Flow cytometric analysis of Jurkat cells, untreated (blue) or LY294002-treated (green), using Akt Antibody compared to a nonspecific negative control antibody (red).
IF-IC

Confocal immunofluorescent images of C2C12 cells showing nuclear and cytoplasmic localization with Akt Antibody (left, red) compared to an isotype control (right). Actin filaments have been labeled with fluorescein phalloidin.
Akt, also referred to as PKB or Rac, plays a critical role in controlling survival and apoptosis (1-3). This protein kinase is activated by insulin and various growth and survival factors to function in a wortmannin-sensitive pathway involving PI3 kinase (2,3). Akt is activated by phospholipid binding and activation loop phosphorylation at Thr308 by PDK1 (4) and by phosphorylation within the carboxy terminus at Ser473. The previously elusive PDK2 responsible for phosphorylation of Akt at Ser473 has been identified as mammalian target of rapamycin (mTOR) in a rapamycin-insensitive complex with rictor and Sin1 (5,6). Akt promotes cell survival by inhibiting apoptosis through phosphorylation and inactivation of several targets, including Bad (7), forkhead transcription factors (8), c-Raf (9), and caspase-9. PTEN phosphatase is a major negative regulator of the PI3 kinase/Akt signaling pathway (10). LY294002 is a specific PI3 kinase inhibitor (11). Another essential Akt function is the regulation of glycogen synthesis through phosphorylation and inactivation of GSK-3α and β (12,13). Akt may also play a role in insulin stimulation of glucose transport (12). In addition to its role in survival and glycogen synthesis, Akt is involved in cell cycle regulation by preventing GSK-3β-mediated phosphorylation and degradation of cyclin D1 (14) and by negatively regulating the cyclin dependent kinase inhibitors p27 Kip (15) and p21 Waf1/CIP1 (16). Akt also plays a critical role in cell growth by directly phosphorylating mTOR in a rapamycin-sensitive complex containing raptor (17). More importantly, Akt phosphorylates and inactivates tuberin (TSC2), an inhibitor of mTOR within the mTOR-raptor complex (18,19).
-
Franke, T.F. et al. (1997) Cell 88, 435-7.
-
Burgering, B.M. and Coffer, P.J. (1995) Nature 376, 599-602.
-
Franke, T.F. et al. (1995) Cell 81, 727-36.
-
Alessi, D.R. et al. (1996) EMBO J 15, 6541-51.
-
Sarbassov, D.D. et al. (2005) Science 307, 1098-101.
-
Jacinto, E. et al. (2006) Cell 127, 125-37.
-
Cardone, M.H. et al. (1998) Science 282, 1318-21.
-
Brunet, A. et al. (1999) Cell 96, 857-68.
-
Zimmermann, S. and Moelling, K. (1999) Science 286, 1741-4.
-
Cantley, L.C. and Neel, B.G. (1999) Proc Natl Acad Sci USA 96, 4240-5.
-
Vlahos, C.J. et al. (1994) J Biol Chem 269, 5241-8.
-
Hajduch, E. et al. (2001) FEBS Lett 492, 199-203.
-
Cross, D.A. et al. (1995) Nature 378, 785-9.
-
Diehl, J.A. et al. (1998) Genes Dev 12, 3499-511.
-
Gesbert, F. et al. (2000) J Biol Chem 275, 39223-30.
-
Zhou, B.P. et al. (2001) Nat Cell Biol 3, 245-52.
-
Navé, B.T. et al. (1999) Biochem J 344 Pt 2, 427-31.
-
Inoki, K. et al. (2002) Nat Cell Biol 4, 648-57.
-
Manning, B.D. et al. (2002) Mol Cell 10, 151-62.
- Asselin, E. et al. (2001) XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 61, 1862-1868. Applications: Western Blot
- Bommakanti, R. K. et al. (2000) Dual regulation of Akt/protein kinase B by heterotrimeric G protein subunits. J. Biol. Chem. 275, 38870-38876. Applications: Western Blot
- Campbell, R. A. et al. (2001) Phosphatidylinositol 3-kinase/Akt-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276, 9817-9824. Applications: Western Blot
- Otero, D. C. et al. (2000) CD19-dependent activation of Akt kinase in B lymphocytes. J. Biol. Chem. 276, 1474-1478. Applications: Western Blotting
- Fukuda, T. et al. (2003) PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival. J. Biol. Chem. 278, 51324-51333. Applications: Western Blotting
- Patrucco, E. et al. (2004) PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375-387. Applications: Western Blotting
- Huang, H. et al. (2001) PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression. J. Biol. Chem. 276, 38830-38836. Applications: Western Blotting
- Meng, F. et al. (2002) Akt Is a Downstream Target of NF-kappaB. J. Biol. Chem. 277, 29674-29680. Applications: Western Blotting
- Zubiaur, M. et al. (2002) CD38 Is Associated with Lipid Rafts and upon Receptor Stimulation Leads to Akt/Protein Kinase B and Erk Activation in the Absence of the CD3-zeta Immune Receptor Tyrosine-based Activation Motifs. J. Biol. Chem. 277, 13-22. Applications: Western Blotting
- Radisavljevic, Z. et al. (2000) Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/nitric oxide pathway and modulates migration of brain microvascular endothelial cells. J. Biol. Chem. 275, 20770-20774. Applications: Western Blot
- Rohani, M.G. et al. (2010) BMC Immunol 11, 53. Applications: Western Blotting
- Chung, Y.W. et al. (2011) J Biol Chem 286, 29681-90. Applications: Western Blotting
- Sykes, S.M. et al. (2011) Cell 146, 697-708. Applications: Western Blotting
- Sakaguchi, M. et al. (2008) Mol Biol Cell 19, 78-85. Applications: Western Blotting
- Yamada, O. et al. (2008) J Leukoc Biol 83, 1240-8. Applications: Western Blotting
- Nakasaki, M. et al. (2008) Bone 43, 869-79. Applications: Western Blotting
- Oneyama, C. (2008) Mol Cell 30, 426-36. Applications: Western Blotting
- Kitamura, T. et al. (2008) Nat Cell Biol 10, 329-37. Applications: Western Blotting
- Nemoto, S. et al. (2009) J Biol Chem 284, 10422-32. Applications: Western Blotting
- Kato, T. et al. (2008) Diabetes 57, 2382-92. Applications: Western Blotting
- Nishioka, Y. et al.(2008) Blood 111, 5086-92. Applications: Flow